98%
921
2 minutes
20
Background: Whether the Glasgow Coma Scale (GCS) can assess intubated patients is still a topic of controversy. We compared the test performance of the GCS motor component (GCS-M)/Simplified Motor Score (SMS) to the total of the GCS in predicting the outcomes of intubated acute severe cerebral vascular disease patients.
Methods: A retrospective analysis of prospectively collected observational data was performed. Between January 2012 and October 2015, 106 consecutive acute severe cerebral vascular disease patients with intubation were included in the study. GCS, GCS-M, GCS eye-opening component, and SMS were documented on admission and at 24, 48, and 72 h after admission to Neurointensive Care Unit (NCU). Outcomes were death and unfavorable prognosis (modified Rankin Scale: 5-6) at NCU discharge. The receiver operating characteristic (ROC) curve was obtained to determine the prognostic performance and best cutoff value for each scoring system. Comparison of the area under the ROC curves (AUCs) was performed using the Z- test.
Results: Of 106 patients included in the study, 41 (38.7%) patients died, and 69 (65.1%) patients had poor prognosis when discharged from NCU. The four time points within 72 h of admission to the NCU were equivalent for each scale's predictive power, except that 0 h was the best for each scale in predicting outcomes of patients with right-hemisphere lesions. Nonsignificant difference was found between GCS-M AUCs and GCS AUCs in predicting death at 0 h (0.721 vs. 0.717, Z = 0.135, P = 0.893) and 72 h (0.730 vs. 0.765, Z = 1.887, P = 0.060), in predicting poor prognosis at 0 h (0.827 vs. 0.819, Z = 0.395, P = 0.693), 24 h (0.771 vs. 0.760, Z = 0.944, P = 0.345), 48 h (0.732 vs. 0.741, Z = 0.593, P = 0.590), and 72 h (0.775 vs. 0.780, Z = 0.302, P = 0.763). AUCs in predicting death for patients with left-hemisphere lesions ranged from 0.700 to 0.804 for GCS-M and from 0.700 to 0.824 for GCS, in predicting poor prognosis ranged from 0.841 to 0.969 for GCS-M and from 0.875 to 0.969 for GCS, with no significant difference between GCS-M AUCs and GCS AUCs within 72 h (P > 0.05). No significant difference between GCS-M AUCs and GCS AUCs was found in predicting death (0.964 vs. 0.964, P = 1.000) and poor prognosis (1.000 vs. 1.000, P = 1.000) for patients with right-hemisphere lesions at 0 h. AUCs in predicting death for patients with brainstem or cerebella were poor for GCS-M (<0.700), in predicting poor prognosis ranged from 0.727 to 0.801 for GCS-M and from 0.704 to 0.820 for GCS, with no significant difference between GCS-M AUCs and GCS AUCs within 72 h (P > 0.05). The SMS AUCs (<0.700) in predicting outcomes were poor.
Conclusions: The GCS-M approaches the same test performance as the GCS in assessing the prognosis of intubated acute severe cerebral vascular disease patients. The GCS-M could be accurately and reliably applied in patients with hemisphere lesions, but caution must be taken for patients with brainstem or cerebella lesions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144850 | PMC |
http://dx.doi.org/10.4103/0366-6999.240813 | DOI Listing |
Langenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFArch Orthop Trauma Surg
September 2025
Orthopaedics and traumatology, Salzburger Landeskliniken, Salzburg, Austria.
Purpose: The NOM (non-operative management) of distal radius fractures (DRF) is influenced by various factors. This study seeks to determine whether poor fracture alignment correlates with poor outcome.
Methods: Over a period of three years, a study was conducted on conservatively treated DRF involving 127 patients, 104 women (81.
Liver Int
October 2025
TGF-Beta and Cancer Group - Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Background And Aims: Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. TGF-β is a promising therapeutic target, but its dual role, as both a tumour suppressor and promoter, complicates its clinical application. While its effects on tumour cells are increasingly understood, its impact on the tumour stroma remains unclear.
View Article and Find Full Text PDFChronobiol Int
September 2025
Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Lung cancer remains one of the most fatal cancers, with cigarette smoke (CS) exposure being a major risk factor due to its role in triggering oxidative stress. Disruption of circadian rhythms, increasingly common in modern lifestyles, has also been linked to cancer progression. Targeting both oxidative imbalance and circadian disruption may offer a more effective therapeutic approach.
View Article and Find Full Text PDFCancer Sci
September 2025
Department of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal chemotherapy regimens and the role of genetic biomarkers in guiding treatment remain unclear. Moreover, predictive markers are urgently needed for radiation-sparing strategies. Therefore, we aimed to assess the predictive and prognostic value of TP53, KRAS, and APC mutations in patients with LARC undergoing neoadjuvant chemotherapy (NACT) by retrospectively analyzing 43 patients with LARC who underwent NACT without radiation.
View Article and Find Full Text PDF